Retatrutide vs CJC-1295 No DAC + Ipamorelin

This is the clearest mechanistic fork in the catalogue: the incretin route, or the growth-hormone route.

Retatrutide acts on receptors in the gut-brain axis — GLP-1, GIP and glucagon, all three addressed by one molecule. CJC-1295 No DAC + Ipamorelin acts on the pituitary, pairing a GHRH analogue with a selective ghrelin-receptor agonist so two upstream signals arrive together. Different organs, different receptor families, different bodies of literature.

The evidence is asymmetric in a way worth naming plainly. Retatrutide's human data is recent, limited and generated under controlled trial conditions. The blend's two components each carry older pharmacology work of their own, but no controlled human study describes the combination as it is sold.

Dosing frequency then distorts the price columns. Published retatrutide protocols are weekly. The blend is used on a shorter cadence and its reconstituted material holds 14 days refrigerated. A weekly compound and a frequently-dosed one consume a vial at very different rates, which the price-per-milligram figure cannot see and does not try to.

So the table above tells you what is in each vial and what it costs to buy. It cannot tell you what it costs to run, and we would rather say that than imply otherwise. Both compounds are supplied lyophilised, stored at 2–8 °C, for laboratory research only, and are not sold for human or veterinary use.